Castor EDC and Veeva Vault EDC are both marketed as electronic data capture systems for clinical trials, but their public documentation leads with different operational priorities. Castor's materials emphasize rapid deployment, open API access, and a broader research ecosystem that can include ePRO, eConsent, and AI-assisted source data extraction [1][2][8]. Veeva's product brief and product sheets emphasize study build speed, elimination of custom functions, amendments without downtime, and connections across a clinical platform that includes CTMS, eTMF, RTSM, and eCOA [9][11][12]. Neither vendor's public pages provide a neutral, side-by-side feature matrix for this exact pair, so any comparison must rely on separately documented claims and stated capabilities. This article organizes those documented differences around the decision points most likely to matter to a clinical data management team: build and amendment workflows, integration and API access, data extraction and review, and platform scope. Where vendor materials do not state a fact, that fact is treated as unknown rather than inferred.
Build Speed and Study Setup
Castor states that it ranks among the top 5% of EDC software providers for shortest platform build time, that low-complexity studies can be deployed in as little as 3-4 weeks, and that build times can be reduced by up to 63% [1][2]. A separate Castor page says more than 90% of its studies are deployed within the first 4 weeks [4]. These figures are vendor-reported and are not accompanied in the retrieved materials by a named external benchmark or a defined denominator for the top 5% ranking. The 63% reduction claim also lacks a stated baseline, so a buyer cannot determine from the public page what comparison produced that number.
Veeva's product page states that Veeva EDC delivers 50% faster study builds, 100% elimination of known custom functions, and 9x faster implementation of study changes [9][10]. The features brief attributes the 50% build speed figure to point-and-click build capabilities, zero custom functions, and a rules engine [11]. Veeva also announces a Study Builder Agent to configure studies in as little as one day, though the retrieved page does not detail the conditions or study types to which that one-day figure applies [9]. Because Castor and Veeva report different metrics against different baselines, the two sets of build-speed claims cannot be directly compared from the available documentation.
Amendment Handling and Study Changes
Castor describes amendment management as a secure, traceable, and validation-friendly process, with full audit trails for every change and separate test environments to validate updates before deployment [1][6]. A Castor page also says forms can be edited mid-study to accommodate protocol amendments [1]. The documentation does not state whether mid-study form edits require downtime, migration, or reversion of completed forms, so the operational impact of a Castor amendment is not fully specified in the retrieved materials.
Veeva's features brief is more explicit about the amendment mechanism. It states that design changes can be made to active studies with no migrations or downtime for sites, and that when new requirements are added, completed forms are reverted to an incomplete state and new fields are flagged for site personnel to populate [11]. Veeva also describes real-time UAT and a system-generated Study Differences Report that documents changes between two builds, which the vendor says eliminates the need for regression testing [11]. These are vendor claims about the product's design, not independently verified outcomes, but they represent a documented difference in how the two vendors describe amendment workflows.
A Suggested Evaluation Workflow for This Pair
A clinical data team could structure a documented evaluation by first listing the study types in its portfolio, then mapping each documented capability to a specific operational requirement. For example, a team planning frequent mid-study amendments might ask Veeva to demonstrate the reversion and flagging behavior described in its features brief, while asking Castor to demonstrate how its test environments and audit trails handle the same amendment [1][11]. A team planning heavy EHR or source-document ingestion might ask Castor to walk through the review policy and 30-day source purge, while asking Veeva to clarify the scope of its announced eSource capability [7][8][10]. This approach is a suggested evaluation method, not a tested workflow, and it should be supplemented with vendor demonstrations and reference checks.
API Access and Integration Approach
Castor publishes API documentation describing a RESTful API with OAuth 2 authentication, including full support for the Client Credentials flow and support for the Authorization Code flow upon request [3]. The documentation lists three OAuth scopes: default, study_statistics, and record [3]. It also states that endpoints are rate-limited to 600 requests in 10 minutes unless otherwise specified [3]. Castor's developer policy describes deprecation procedures, sunset dates communicated through HTTP headers, and status categories for Beta, Stable, Deprecated, and Retired API elements [5]. This level of public API documentation is a concrete, verifiable difference in the retrieved materials.
Veeva's product brief mentions a high-volume Export API, but the retrieved pages do not include equivalent public endpoint documentation, authentication details, or rate-limit specifications for Veeva EDC [11]. Veeva instead emphasizes productized connections built and maintained by Veeva, which the vendor says eliminate maintenance costs and upgrade risks for critical integrations [11]. The product sheet lists Veeva EDC as connected with DQS, RTSM, eCOA, CTMS, eTMF, Payments, and Safety [12]. Whether Veeva offers the same depth of public API documentation as Castor is unknown from the public documents; the absence of such documentation in the retrieved set should not be read as proof that no API exists.
AI Data Extraction and Source Document Workflow
Castor's AI clinical data extraction service is documented as sitting between source documents and the EDC. The workflow includes intake through a Source Gateway, redaction, AI extraction, and human review, with a stated policy that today every value is sent to a Castor reviewer [7]. Castor reports internal benchmarking figures of 6 minutes per chart for this service versus 39 minutes manually, and $9.75 per chart versus $48.75 manually, while noting that the manual error rate figure comes from a 2025 meta-analysis and that Castor figures are internal benchmarks, production telemetry, or anonymised case results, not peer-reviewed [7]. The service supports site upload globally and direct-to-patient EHR retrieval in the US via HIPAA release, TEFCA, or FHIR API [8].
The retrieved Veeva materials do not describe a comparable AI source-document extraction workflow for Veeva EDC. Veeva's pages focus on EDC data collection, querying, targeted SDV, protocol deviations, data lock, and post-processing [9][10][12]. Veeva does announce Veeva eSource to eliminate paper and simplify data flow, but the retrieved page does not detail how eSource handles extraction, redaction, or human review [10]. A buyer evaluating AI-assisted data entry should therefore treat Castor's documented AI extraction workflow as a specific capability and Veeva's equivalent capability as unknown from the public documents.
Platform Scope and Customer Settings
Castor positions its EDC as part of an all-in-one clinical trial platform that can include remote enrollment, screening, eConsent, ePRO, native diary apps, video calls, wearables, and EHR data [1][2]. The vendor also lists compliance with FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, ISO 27001, and ISO 9001, and alignment with HL7 FHIR [1][6]. These are vendor statements of compliance scope, not certifications verified in the retrieved documents. Castor's materials include customer quotations from Essity, Cadex Genomics, Lucira Health, and Rodin Scientific, but those quotations describe individual experiences and do not establish a market-wide performance pattern [2][4].
Veeva describes Veeva EDC as part of a clinical platform that includes CDB, eCOA, RTSM, eTMF, Site Connect, Study Training, CTMS, Payments, and Safety [11][12]. The product sheet lists Veeva EDC as announced in 2016, with a status of Mature and more than 100 customers, and identifies the customer type as Enterprise Pharma, Biotech, Consumer Health, MedTech, and CRO [12]. Veeva states that eight of the top 20 biopharmas switched to Veeva EDC and names Alcon, Cara, Fortrea, GSK, Idorsia, Kronos-Bio, LEO, Lotus, Platform-Life-Sciences, Syneos, and Vertex [9][10]. That list reflects Veeva's stated customer base, not a neutral market share calculation.
Sources & references
- Castor · www.castoredc.com
- Electronic Data Capture (EDC) Software for Clinical Trials · castoredc.com
- Castor EDC API Documentation · data.castoredc.com
- Electronic Data Capture (EDC) Software for Clinical Trials · www.castoredc.com
- API Developer Policy – Castor · helpdesk.castoredc.com
- Castor · www.castoredc.com
- How Castor Catalyst works: source documents in, study data out · www.castoredc.com
- Catalyst: AI clinical data extraction for trials | Castor · www.castoredc.com
- Electronic Data Capture for Advanced Clinical Studies | Veeva · www.veeva.com
- Electronic Data Capture for Advanced Clinical Studies | Veeva · www.veeva.com
- Veeva EDC Features Brief | Veeva · www.veeva.com
- Product Sheets · www.veeva.com